PRESS RELEASE

March 14, 2011

Meiji Seika Kaisha, Ltd. and RaQualia Pharma Inc. Sign License Agreement for Ziprasidone

March 14, 2011 – Meiji Seika Kaisha, Ltd. (Meiji), President & CEO: Naotada Sato, headquartered in Chuo-ku, Tokyo, Japan and RaQualia Pharma Inc. (RaQualia), President & CEO: Atsushi Nagahisa, headquartered in Chita-gun, Aichi, Japan, today announced the signing of a Licensing Agreement for the 2nd generation (atypical) antipsychotic drug, ziprasidone.

Under the terms of the agreement, Meiji will have exclusive rights in Japan to develop and commercialize ziprasidone. In return, RaQualia will receive an upfront payment and is eligible to receive development milestones and royalties on commercial sales. RaQualia received the right to commercialize ziprasidone in Japan from Pfizer Inc.

Schizophrenia is a mental disorder which commonly manifests itself via auditory hallucinations, paranoia, and various other symptoms. It has a prevalence rate of approximately 1%. Ziprasidone is an atypical antipsychotic drug and demonstrates antagonistic efficacy on both the dopamine D2 receptor and serotonin 5-HT2B receptor. Developed by Pfizer Inc, ziprasidone is currently marketed in 76 countries, with worldwide sales totalling over (US) $1 billion in 2010. Ziprasidone has some advantages over other currently available 2nd atypical antipsychotic drugs, including a low risk of body weight gain and blood sugar level increase. Ziprasidone is regarded as a first-choice drug in its class, according to guidelines for treatment of mental disorders in the United States.

Meiji and RaQualia will collaborate to launch ziprasidone in Japan at the earliest possible date, using a rich collection of global clinical test data.

###

Note: This press release has been translated based upon the Japanese press release made by RaQualia Pharma Inc. on March 14, 2011. Please refer to the Japanese-language version as the original document.

Contact:
RaQualia Pharma Inc.
Tim Kendall
E-mail: ask@raqualia.com